Change over period: —
NSE · INNOVACAP
INNOVACAP
-19.1% from the 52-week high · +62.9% above the low
Innova Captab Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Panchkula, Haryana. The company went IPO on 2023-12-29. Innova Captab Ltd is an integrated pharmaceutical company. The firm is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. The company has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.
The short version. INNOVACAP reported revenue of ₹496 crore for Sep 2026, up 30.5% from a year earlier. Net profit was ₹42 crore (up 40.0% year on year). Return on equity was 13.2% in Mar 2026. Promoter holding was 50.9% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
INNOVACAP trades 19.1% below its 52-week high and 62.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹496 cr.
Sep 2026 net profit of ₹42 cr.
0.7 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 496 | 471 | 448 | 450 | 380 | 352 | 315 | 316 |
| Net profit | 42 | 44 | 40 | 42 | 30 | 31 | 30 | 34 |
| Net margin % | 8.5 | 9.4 | 9.0 | 9.4 | 7.8 | 8.8 | 9.4 | 10.8 |
| EPS (₹) | 7.41 | 7.71 | 7.05 | 7.37 | 5.18 | 5.42 | 5.17 | 5.98 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 1630 | 1244 | 1081 |
| Net profit | 143 | 128 | 94 |
| Net margin % | 8.8 | 10.3 | 8.7 |
| EPS (₹) | 25.02 | 22.41 | 16.49 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 13.2% in Mar 2026; debt to equity is 0.32.
Profitability · 3 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Return on equity % | 13.2 | 13.4 | 11.3 |
| Return on capital % | 15.3 | 14.1 | 14.3 |
| EBITDA margin % | 15.3 | 15.8 | 15.3 |
| Net margin % | 8.7 | 10.2 | 8.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 0.1 pts over 8 quarters.
Down 0.8 pts over 8 quarters.
+6 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.9 | 50.9 | 50.9 | 50.9 | 50.9 | 50.9 | 50.9 | 50.9 | 0.0 |
| FII | 0.74 | 0.34 | 0.23 | 0.08 | 0.11 | 0.23 | 0.34 | 0.84 | +0.1 |
| DII | 19.96 | 19.76 | 19.67 | 20.17 | 20.24 | 20.14 | 19.92 | 19.16 | -0.8 |
| Public | 28.41 | 28.99 | 29.2 | 28.85 | 28.76 | 28.73 | 28.84 | 29.09 | +0.68 |
Mutual fund holdings · Oct 2026
18 schemes hold this stock
12 the month before.
- CANARA ROBECO MANUFACTURING FUND1.76% of NAV
- SBI Balanced Hybrid Fund1.42% of NAV
- SBI Healthcare Opportunities Fund1.41% of NAV
- Kotak Consumption Fund1.38% of NAV
- CANARA ROBECO SMALL CAP FUND1.23% of NAV
- Kotak Healthcare Fund1.19% of NAV
- CANARA ROBECO VALUE FUND1.19% of NAV
- Invesco India Manufacturing Fund1.14% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for INNOVACAP are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about INNOVACAP
What is the INNOVACAP share price?
INNOVACAP (INNOVACAP) last closed at ₹1,005.30, down 4.27% on the day. Its 52-week range is ₹644.75 to ₹1,297.60.
What is the market cap of INNOVACAP?
INNOVACAP has a market capitalisation of about ₹6,004 crore. Its price-to-earnings ratio is 38.4.
How are INNOVACAP's latest results?
INNOVACAP reported revenue of ₹496 crore for Sep 2026, up 30.5% from a year earlier. Net profit was ₹42 crore (up 40.0% year on year). Return on equity was 13.2% in Mar 2026. Promoter holding was 50.9% in Sep 2026, up 0.00 points over 8 quarters.
Who owns INNOVACAP?
As of Sep 2026, shareholding was: Promoter 50.9%, FII 0.84%, DII 19.16%, Public 29.09%.
How many mutual funds hold INNOVACAP?
18 mutual fund schemes held INNOVACAP in October 2026. That compares with 12 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 30 Jan 2026 · Interim Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.